The Drug-Dosing Conundrum in Oncology — When Less Is More
Mirat Shah, Atiqur Rahman, Marc R. Theoret, Richard Pazdur
Abstract
Doses and schedules of oncology drugs are sometimes inadequately characterized before registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches to dose optimization.
Topics & Concepts
MedicineDosingDrugIntensive care medicineClinical trialOncologyDrug approvalPharmacologyMedical physicsInternal medicineStatistical Methods in Clinical TrialsLung Cancer Treatments and MutationsCancer Genomics and Diagnostics